Stay updated on AFM24 + Atezolizumab in EGFR+ Cancers Clinical Trial
Sign up to get notified when there's something new on the AFM24 + Atezolizumab in EGFR+ Cancers Clinical Trial page.

Latest updates to the AFM24 + Atezolizumab in EGFR+ Cancers Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe temporary NIH notice about its terminology transition was removed from the top of the page; the 403 error message remains.SummaryDifference1%

- Check20 days agoChange DetectedThe footer shows the site revision changing from v3.7.2 to v3.8.0, while the study page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check27 days agoChange DetectedA banner announces NIH’s transition terminology update, stating that federal agencies are using “Super Intelligence” in place of “Artificial Intelligence.”SummaryDifference1%

- Check34 days agoChange DetectedThe footer’s displayed site revision changes from v3.7.1 to v3.7.2; the page remains a 403 Forbidden error screen.SummaryDifference0.2%

- Check41 days agoChange DetectedThe footer revision identifier changed from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check62 days agoChange DetectedThe page now displays a 403 Forbidden error, indicating the study record is currently inaccessible. This affects page accessibility but not the underlying study information.SummaryDifference18%

Stay in the know with updates to AFM24 + Atezolizumab in EGFR+ Cancers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the AFM24 + Atezolizumab in EGFR+ Cancers Clinical Trial page.